Rhythm Pharmaceuticals
RYTM
112.36
-4.44
-3.80%
Rhythm Pharmaceuticals
US · RYTM
#1874 by market cap
Listed 2017
112.36
-4.44
-3.80%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $159Market Newswire · 2026/10/8
-
Rating change
Wolfe Research Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy RatingMarket Newswire · 2026/9/17
-
Rating change
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $150Market Newswire · 2026/8/25
-
Rating change
J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)TipRanks · 2026/9/16
-
Rating change
Rhythm Pharmaceuticals (RYTM) Receives a Buy From H.C. WainwrightTipRanks · 2026/10/12
-
Rating change
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy RatingMarket Newswire · 2026/10/9
-
Citizens JMP Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $166Market Newswire · 2026/11/4
-
Rating change
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120Market Newswire · 2026/8/28
-
Rating change
J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $145Market Newswire · 2026/10/15
-
Rating change
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $143 to $166Market Newswire · 2026/11/5
-
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $168Market Newswire · 2026/11/5
-
Rating change
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143Market Newswire · 2026/10/20
-
Rating change
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $130Market Newswire · 2026/10/12
-
Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $150Market Newswire · 2026/11/4
-
Rating change
J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy RatingMarket Newswire · 2026/9/16
-
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $147Market Newswire · 2026/11/5
-
Rating change
RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155Market Newswire · 2026/9/15
-
J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Cuts Target Price to $142Market Newswire · 2026/11/6
-
Rating change
William Blair Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $206Market Newswire · 2026/10/16
-
Rating change
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $160Market Newswire · 2026/8/5
-
Rating change
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $150Market Newswire · 2026/8/5
-
Rating change
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151Market Newswire · 2026/7/8
-
Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143Market Newswire · 2026/10/28
-
Rating change
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $154Market Newswire · 2026/8/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rhythm Pharmaceuticals discussion 0 comments